Predicting the outcome of ankylosing spondylitis therapy - Wikidata - wikimedia - TriplyDB

Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

http://www.wikidata.org/entity/Q34905433

about

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis Old and new treatment targets in axial spondyloarthritis Pharmacogenetics of treatment response in psoriatic arthritis Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis.Incidence and predictors of morphometric vertebral fractures in patients with ankylosing spondylitis.Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Body mass index influences the response to infliximab in ankylosing spondylitis Management and evaluation of extra-articular manifestations in spondyloarthritis Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab Biologics Use in Asian Indian Patients with Ankylosing Spondylitis: A Physician's Perspective.Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial.Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers.Quantitative Proteomic Analysis of Peripheral Blood Mononuclear Cells in Ankylosing Spondylitis by iTRAQ.Emerging drugs for axial spondyloarthritis including ankylosing spondylitis.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.Emerging drugs for the treatment of axial and peripheral spondyloarthritis.Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes.The role of MRI in the evaluation of spondyloarthritis: a clinician's guide.An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis.Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease.Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.Axial spondyloarthritis: is there a treatment of choice?Opinion: Perspectives on imaging in axial spondyloarthritis.Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index in Turkish patients with ankylosing spondylitis: relationship with disease activity and quality of life.Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study.Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis.Unmet Needs in Axial Spondyloarthritis.

P2860

Q26774173-6ED92B21-5B49-44B9-B58E-BF7261D01A82 Q26777906-684E5A00-6555-42E4-9E92-1CC8A455B011 Q28081252-D29FDE94-EF00-4B2E-B808-F205941F2B45 Q30776497-C4797CBA-D3B2-40F9-B122-AEADF85A9599 Q33584246-95208913-F2BB-4BAE-9AA4-A992EE501208 Q33892405-615ACAB3-CA3F-4CBF-93A7-EEAA1204B7B7 Q34570563-D3FC6536-3683-4722-9507-095066C894DF Q35768646-96EDEA68-E39F-40AB-8A22-FC452950EBFB Q35896670-8583636F-19BE-42D6-BCC4-C9158617BE28 Q36245977-EF7FB718-144C-4D97-901E-F6460435129C Q36439889-71365E38-3379-49C2-B25C-DBF07A32DBA1 Q36477447-00A4C99B-EA87-4D8A-9894-4B9544741544 Q36674075-6EFA37FA-0AB9-4D08-B1BA-D2AA11B7E31B Q36715135-66E7DDB1-A4B5-494A-AAD3-95119B5C9618 Q36876679-068A57D7-4FBB-42F9-A857-9AB3AA61A03A Q37118948-DAF41AC8-608A-4E8E-9BEA-0529803ABAD8 Q37250836-26062AF9-741D-467C-8BFB-01FB23140BF2 Q37502434-156D88AD-B931-4494-A870-92AB53DF18D8 Q37690041-9110D004-6F07-4C04-9EA3-D26EF4576706 Q37700822-EE3AA3E1-49B0-4D97-83F3-8447E24C5197 Q38068578-20C3BC86-0A50-48A6-A369-FDF13C27F987 Q38198090-C86A9C6A-BA82-407F-B942-D9A90688125A Q38203474-CCA38797-1DD1-43B0-8CF0-249F1BB48726 Q38313266-3779CD81-66F4-4F63-B9AA-2EDA9FD8E9A5 Q38517691-9D16AF3E-B4EC-482B-B809-7E6CEAA2E5AE Q38812331-C39EE229-2FDF-4C79-A37C-D8B6F15F0D71 Q38914839-E14AECF0-E7FE-4761-83E8-8272851802ED Q39225803-3FB3A78B-233E-4AAC-8004-E7E33DD56317 Q39328197-6F8993C0-7541-497B-B241-BAEA18CD83B4 Q40042219-4E111CE8-6855-4691-9D0D-920F81502A29 Q40251018-334AD7BD-C936-45F8-9DA5-CBDBBC07D5B7 Q41456495-2B0B00FE-828F-4D88-A87E-6B6420407E32 Q42013856-6448FEFB-6E9A-4C3F-BDE3-A0D6F25D6D05 Q42604065-D94B59D0-03CF-4DDD-86F2-68DDD8811AAC Q43527556-49031DCC-26EA-4429-958F-ED088B24D878 Q44429588-1843C977-CF91-4C63-8570-D55E9195E9D2 Q45229094-68B9D85B-273C-45BA-9D6F-BD10D15E7DBA Q46070866-3096A2E8-48DB-47D3-BC34-F95BC9F728BA Q48132271-C1EC3F88-4B2D-4DB4-AB68-A0C9328CE98A Q48287506-7DA88FEF-8C77-48BC-9498-EAEDFD613E2D

P2860

Predicting the outcome of ankylosing spondylitis therapy

http://www.wikidata.org/entity/Q34905433

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Predicting the outcome of ankylosing spondylitis therapy

@ast

Predicting the outcome of ankylosing spondylitis therapy

@en

Predicting the outcome of ankylosing spondylitis therapy

@nl

type

label

Predicting the outcome of ankylosing spondylitis therapy

@ast

Predicting the outcome of ankylosing spondylitis therapy

@en

Predicting the outcome of ankylosing spondylitis therapy

@nl

prefLabel

Predicting the outcome of ankylosing spondylitis therapy

@ast

Predicting the outcome of ankylosing spondylitis therapy

@en

Predicting the outcome of ankylosing spondylitis therapy

@nl

P1433

Q34905433-BC9A81E6-9B1B-45A5-9AC7-DA020DF08F9C

P1476

Q34905433-6AC3CD8E-A5FF-49AA-82AA-D37ED168755C

P2093

Q34905433-0A746FCA-E4B9-4869-96C1-2E1DF7E063C3

Q34905433-30295F52-8C8C-41CF-86A1-76ADFACB2A25

Q34905433-32317954-AF6D-4DD6-A1EC-F3259FB0EAFD

Q34905433-33F3AE41-D1E3-4B7D-8748-817900CAFD11

Q34905433-46781F6A-4F3F-4FFF-8CB8-2C6B3CAA495F

Q34905433-5B6F7553-3041-46D5-9308-62F9D896558D

Q34905433-92EFE918-9D19-400F-B187-981AA7725AC8

Q34905433-A8432C2B-2F0D-4857-BBE8-7BA20D055DF4

Q34905433-D01AACAB-AFD4-4C7A-A979-0927501A6195

Q34905433-DA90B588-6B8E-4910-B9D9-C09FC43A8BF0

P2860

Q34905433-03E78E62-07A9-4058-A317-07786C464F5D

Q34905433-0F3EEDCD-84AF-4525-A682-31233B42C515

Q34905433-157C321C-481B-47B5-917B-BF34B04B82F2

Q34905433-1CDCB541-4600-44F1-86F2-5434D3123A5C

Q34905433-244C445D-7DA1-47F0-AC9B-41D9A56CF813

Q34905433-3418BB79-E48E-45E5-B1C0-EA78EBA984D0

Q34905433-36940B87-9836-4BFE-999A-DBE007CCCE35

Q34905433-3E838392-F4C3-4724-A5CA-CA669357E02D

Q34905433-4B681D56-D440-498B-AFCD-7FAF6E4AC538

Q34905433-6DBF9D94-3AA2-4A8B-8686-8E302436C597

P304

Q34905433-6D82FEB4-5BD2-45C7-9E04-73CAFF791F9E

P31

Q34905433-14AD7829-908E-4AD5-A94D-C211AE0830E4

P356

Q34905433-34BC1503-6DEB-4309-A91C-1D838EE47C4D

P407

Q34905433-FB7FC5DB-1197-4761-A3C7-F6AEAAF386EB

P433

Q34905433-51ED5170-3F09-411A-9211-066BD1F1503B

P478

Q34905433-3E15A414-3C1A-4183-B9AE-AD38D8263DB7

P50

Q34905433-3E4FB6FF-E341-47F0-86F7-8662E5A64E89

Q34905433-6D9B6CA3-5334-428B-B591-C9BA18792A50

P577

Q34905433-65C0BB97-4F5D-4A7D-B64D-8A71A3A9E8F3

P5875

Q34905433-981EA3AC-72F5-4C96-B18C-F371B6B825B8

P698

Q34905433-C431BACB-9B41-4C78-9E27-8A0041512D20

P932

Q34905433-D5A0F886-AE21-47EE-9439-8A988B6D8D4C

P356

ARD.2010.147744

P1433

Annals of the Rheumatic Diseases

P1476

Predicting the outcome of ankylosing spondylitis therapy

@en

P2093

Atul Deodhar

http://www.w3.org/2001/XMLSchema#string

Ben Dijkmans

http://www.w3.org/2001/XMLSchema#string

Benjamin Hsu

http://www.w3.org/2001/XMLSchema#string

Bert Vander Cruyssen

http://www.w3.org/2001/XMLSchema#string

Désirée van der Heijde

http://www.w3.org/2001/XMLSchema#string

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

Jürgen Braun

http://www.w3.org/2001/XMLSchema#string

Mahboob U Rahman

http://www.w3.org/2001/XMLSchema#string

Nathan Vastesaeger

http://www.w3.org/2001/XMLSchema#string

Piet Geusens

http://www.w3.org/2001/XMLSchema#string

P2860

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

ASAS/EULAR recommendations for the management of ankylosing spondylitis.

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.

Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

P304

973-981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2010.147744

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Eduardo Collantes Estévez

Robert D. Inman

P577

2011-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50394752

http://www.w3.org/2001/XMLSchema#string

P698

21402563

http://www.w3.org/2001/XMLSchema#string

P932

3086037

http://www.w3.org/2001/XMLSchema#string